News
Press Releases
2020/08/13
WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations
(SHANGHAI, August 13, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its reviewed financial results for the first half of 2020 (Reporting Period).
Read more2020/06/01
WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit
SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Development and Manufacturing Organization (CDMO). In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services.
Read more2020/05/18
WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform
May 18, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advanced therapies industry, announced today the expansion of its service capabilities to offer a fully integrated Closed Process CAR-T Cell Therapy Platform. This new platform will accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.
Read more2020/04/29
WuXi AppTec Reports Solid First-Quarter 2020 Results
SHANGHAI, April 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter 2020 ("Reporting Period").
Read more2020/03/24
WuXi AppTec Reports Strong 2019 Annual Results
(SHANGHAI, March 24, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2019 (“Reporting Period”).
Read more